News

OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential …

China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

On 24 January 2017, OBI Pharma, Inc. (4174) received formal …

OBI Pharma holds EOP2 meeting with US FDA

OBI Pharma, Inc. has met with the Office of Tissues …

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with …

OBI Pharma Awarded Level-A Recognition for TIPS Management

OBI Pharma, Taiwan (4174) announced that it has been awarded …

OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

OBI Pharma, Taiwan (4174) announced that it has been granted …

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

OBI Pharma is pleased to provide video highlights from the …

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

In response to Next Magazine’s continuous and malicious publication of …

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

Experts Examine the Future of Active Immunotherapy in Oncology and …

Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”

Some media have reported on Dr. Michael Chang, the Chairman …